Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT non-squamous NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France

During the meeting I presented the patient-reported outcomes from the LUMINOSITY trial. LUMINOSITY is a second-line trial in metastatic non-small-cell lung cancer for patients with an overexpression of c-Met at immunohistochemistry. It’s a selected subset of patients. LUMINOSITY was reported at the last ASCO meeting, it’s a two-part, phase II trial conducted in non-small cell lung cancer patients, squamous, non-squamous, EGFR wildtype, EGFR mutant, and finally dose expansion was conducted in EGFR wildtype non-squamous cell carcinoma patients. This is something like 160 patients.

LUMINOSITY met its primary endpoint, prespecified overall response rate, 29% in this patient population and up to 35% in c-Met high tumours. So very interesting data. A phase III trial is ongoing, TeliMET, comparing Teliso-V, this ADC blocking agent that was assessed in LUMINOSITY, versus docetaxel.

With regard to the patient-reported outcomes, it’s very interesting to see that patients are reporting symptoms modification, based on the safety efficacy profile of Teliso-V. We see an improvement in chest pain and cough, which are key cancer-related symptoms, and this is related to the response rate. The improvement in those symptoms is even higher in c-Met high patients so it’s really correlated with response rate. We also see a deterioration in peripheral neuropathy as reported by the patients. Peripheral neuropathy is the most frequent adverse event related to Teliso-V: 40% of patients in LUMINOSITY, 10% with a grade 3 neuropathic event.

All of the other parameters were maintained along with the delivery of Teliso-V. We are also interested in looking at the time to deterioration of quality of life, and it was interesting to see that time to deterioration of quality of life was actively more prolonged not only in the responders, as expected, but also in patients with stable disease, with control of the disease. It means that with this ADC, Teliso-V, it’s not only a matter of response but it’s also a matter of disease control, of stable disease, as reported by the patients. It means that for these patients with aggressive disease, second-line metastatic non-small-cell lung cancer, achieving stable disease means something in terms of quality of life and physical function.

TeliMET is now ongoing, the phase III trial comparing Teliso-V to docetaxel, with a primary endpoint of PFS and response rate, and also quality of life endpoints.